BE491927A - - Google Patents

Info

Publication number
BE491927A
BE491927A BE491927DA BE491927A BE 491927 A BE491927 A BE 491927A BE 491927D A BE491927D A BE 491927DA BE 491927 A BE491927 A BE 491927A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication of BE491927A publication Critical patent/BE491927A/xx
Priority to US669782XA priority Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
BE491927D 1948-10-30 BE491927A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US669782XA true 1948-10-30 1948-10-30

Publications (1)

Publication Number Publication Date
BE491927A true BE491927A (en)

Family

ID=22072944

Family Applications (1)

Application Number Title Priority Date Filing Date
BE491927D BE491927A (en) 1948-10-30

Country Status (3)

Country Link
BE (1) BE491927A (en)
FR (1) FR1011528A (en)
GB (1) GB669782A (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2811483A (en) * 1954-12-09 1957-10-29 Pfizer & Co C Pharmaceutical composition and process for preparing the same
FR1172087A (en) * 1956-01-25 1959-02-05 Bellon Labor Sa Roger Improvements concerning the coating of delayed effect preparations and sustained effect
US2921001A (en) * 1957-04-16 1960-01-12 Sterling Drug Inc Multi-layered pill or tablet with indicating lamination
NL235736A (en) * 1958-02-03
GB906422A (en) * 1958-05-02 1962-09-19 Wellcome Found Improvements in and relating to prolonged acting pharmaceutical preparations
US3131123A (en) * 1959-03-13 1964-04-28 Lab Francais De Therapeutique Enteric tablets and manufacture thereof
US3181998A (en) * 1960-08-12 1965-05-04 Joseph L Kanig Tablet disintegration
US3147187A (en) * 1962-09-10 1964-09-01 Don Hall Lab Sustained release pharmaceutical
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373693A4 (en) 2009-01-06 2012-04-25 Curelon Llc Compositions and methods for the treatment or the prevention oral infections by e. coli
ES2668909T3 (en) 2009-01-06 2018-05-23 Galenagen, Llc Compositions comprising protease, amylase and lipase for use in the treatment of Staphylococcus aureus infections
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2011159798A2 (en) * 2010-06-15 2011-12-22 University Of South Florida A method of modulated exothermic chemical systems through phase change materials
EP2616048A4 (en) * 2010-11-19 2014-04-02 Curemark Llc Preparation and use of combination enzyme and gastrointestinal modulator delivery systems
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
GB669782A (en) 1952-04-09
FR1011528A (en) 1952-06-24

Similar Documents

Publication Publication Date Title
BE487233A (en)
BE485082A (en)
BE488988A (en)
BE488061A (en)
BE488126A (en)
BE487995A (en)
BE488814A (en)
BE488081A (en)
BE488874A (en)
BE489126A (en)
BE487194A (en)
BE488963A (en)
BE487069A (en)
BE487839A (en)
BE487365A (en)
BE486823A (en)
BE487326A (en)
BE488207A (en)
BE487692A (en)
BE486935A (en)
BE487149A (en)
BE487229A (en)
BE487482A (en)
BE484886A (en)
BE487865A (en)